Ballicules.com

Bethanechol

URECHOLINE

What it isMuscarinic agonist resistant to cholinesterase; urinary retention and neurogenic bladder.

Why this oneIt stimulates detrusor contraction without nicotinic effects.

What limits itContraindicated in bladder outlet obstruction, where it can cause rupture. Bronchospasm, bradycardia and cramping.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Urinary retention / neurogenic bladderAdults5-10 mg, repeat hourly until response or max 50 mg reached10-50 mg TID-QID50 mg per test dose sequence

Renal Undefined

Hepatic Undefined

Minimum effective dose determined by giving 5-10 mg and repeating same amount at hourly intervals until response or 50 mg total

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Undefined

Lactation Undefined

NO BOXED WARNINGS

Principal riskContraindicated in outlet obstruction; bronchospasm

Cost, est. cash$5–$150/month

Generic entry1983

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Bethanechol ballicule

Bethanechol ballicule: receptor binding, kinetics and half-life diagram

Open Bethanechol in the interactive console ↗

Memory aids: mascots and interaction avatars

Bethanechol URECHOLINE mascot mnemonic cartoon
“Bath of ‘choline / Urine ‘choline”
baby blue theme → muscarinic
Bethanechol no kinetic interactions avatar
no kinetic interactions

Open Bethanechol in the interactive console ↗